(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Latest News Releases From The Newsroom

Earnings Reaction Roundup: DLocal Surges, Mercury Systems Dips

August 15th, 2023

DLocal Limited (Nasdaq: DLO), a global payments technology company, reported second-quarter 2023 earnings of $0.15 per share, surpassing the consensus EPS estimate of $0.13. The company's quarterly sales amounted to $161.00 million, exceeding analyst. Read more

HUYA and Home Depot Surpass Estimates, Unveil Share Buyback Programs

August 15th, 2023

HUYA Inc. (NYSE: HUYA), a leading game live streaming platform in China, posted second-quarter 2023 adjusted earnings per American depositary share (ADS) of $0.06, surpassing the consensus estimate of $0.01. The company's quarterly sales amounted to . Read more

$250M Share Buyback Boosts Seadrill; Tencent Music Misses Estimates

August 15th, 2023

Shares of Seadrill Limited (NYSE: SDRL) surged in pre-market trading as the company unveiled an up to $250 million share buyback program Seadrill also disclosed total operating revenues of $414 million in its second-quarter 2023 results, reflectin. Read more

Momentum Building: Delcath Systems Spikes on HEPZATO KIT's FDA Nod

August 15th, 2023

Shares of Delcath Systems, Inc. (Nasdaq: DCTH) surged over 50% following the announcement of FDA approval for HEPZATO KIT (melphalan/Hepatic Delivery System).  This liver-directed therapy is now authorized for adult patients battling metastat. Read more

Q2: SCYNEXIS Surpasses Forecasts; Nogin Misses the Mark

August 14th, 2023

SCYNEXIS, Inc. (Nasdaq: SCYX), a biotechnology company, reported second-quarter 2023 earnings of $2.46 per share, surpassing the consensus estimate of $1.55 per share. The company posted quarterly sales of $131.50 million, exceeding analysts' project. Read more

Crown Equity Holdings, Inc. Announces Cancellation of Letter of Intent With Level Finish LLC

August 14th, 2023

LAS VEGAS, NV  / CRWE PRESS RELEASE / August 14, 2023 / Crown Equity Holdings, Inc. (OTC PINK:CRWE) today announced the cancellation of its Letter of Intent with Level Finish LLC, which was announced on February 27, 2023, effective immediately. . Read more

Q2: Plus Therapeutics Beats Estimates, Eos Energy Falls Short

August 14th, 2023

Plus Therapeutics, Inc. (Nasdaq: PSTV), a pharmaceutical company, delivered a second-quarter 2023 loss of $(0.59) per share, surpassing the consensus estimate loss of $(1.91) per share. The company posted quarterly sales of $1.85 million, outperformi. Read more

SEC Charges UK Audit Firm, CEO, and Senior Auditor for Failures in Connection with De-SPAC Transaction

August 14th, 2023

FOR IMMEDIATE RELEASE 2023-152 Washington D.C. / CRWE PRESS RELEASE / Aug. 14, 2023 -  The Securities and Exchange Commission today charged Crowe U.K. LLP, a London based audit firm, its CEO, Nigel Bostock, and senior auditor, Matthew S. Read more

Bullish Stance on Agilysys and Coterra Energy

August 14th, 2023

Agilysys, Inc. (Nasdaq: AGYS), a provider of innovative hospitality software solutions, garnered attention as Needham initiated coverage with a Buy rating and a price target of $92. With $AGYS closing at $70.08 on Friday, this price target implies. Read more

DouYu Beats Forecasts; Goldman Sachs Bullish On Teledyne

August 14th, 2023

DouYu International Holdings Limited (Nasdaq: DOYU) reported second-quarter 2023 earnings of $0.03 per share, surpassing the consensus estimate of $0.00. Additionally, DouYu achieved quarterly sales of $191.99 million, outperforming analysts' project. Read more